We are an enterprise integrating chemical research and development, production and trading, specializing in the operation of high-quality fine chemical products.
Company adopts an advanced management model, possesses a professional R&D team, strong technical strength, a complete quality assurance and control system, excellent sales and after-sales service, forming a complete system from product R&D, production, sales to after-sales service, ensuring the highest quality and timely delivery.
We are extremely committed to the collection and research and development of both new and old products. Adhering to the business philosophy of "sincerity and trustworthiness, customer satisfaction first", we follow the path of professional development and have won high praise and a good reputation from customers with excellent product quality and perfect and considerate services. To become a leading import and export enterprise of pharmaceuticals and chemicals in China. Processing capacity: The company has strong technical force and advanced testing equipment, and can provide high-quality products ranging from gram level to kilogram level and ton level. After-sales service: Made in China, reasonable price, superior quality. 24-hour online service. 3. Safe and fast global delivery. 4. High-quality after-sales service with customer satisfaction as the goal.
B7-33 is a novel, synthetic compound that was first discovered and developed by a team of researchers at the Monash University in Australia. The development of B7-33 was based on the discovery of the relaxin receptor 1 (RXFP1) and the recognition of its potential as a therapeutic target for a wide range of diseases and conditions.
The research team, led by Professor David Handelsman, first synthesized B7-33 in the early 2010s as part of their efforts to develop a functionally selective agonist for RXFP1. This compound was then tested in a series of in vitro and in vivo studies, which demonstrated its potential as a treatment for hypertension, kidney disease, and heart failure. The team's research on B7-33 was published in several scientific journals, including the Journal of Biological Chemistry and the Journal of Hypertension.
These publications highlighted the compound's unique mechanism of action and its potential as a treatment option for patients.
Quality First Safety Guaranteed

Send a Message
We'd love to hear from you if you have any questions!